Kymera Q4 net loss $70.8M, cash $851M; KT-621 Phase 1 data June 2025

Kymera Therapeutics, Inc.

2024-FY EPS reported -$2.98 revenue$47,072,000

Net loss Q4 2024 $70.8M, full year $223.9M; collaboration revenue Q4 $7.4M vs $47.9M YoY.
Cash $851M as of Dec 31, 2024; runway into mid-2027.
KT-621 Phase 1 SAD/MAD data June 2025; Phase 1b AD starts 2Q25 with data 4Q25; Phase 2b AD/asthma 4Q25/1Q26.
KT-295 (TYK2) Phase 1 starts 2Q25 with data 4Q25; new first-in-class program announced May 2025.
Director Leigh Morgan not standing for reelection; no disagreement with company.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Leigh Morgan

Director

KYMR · Kymera Therapeutics, Inc.

Filed: February 27, 2025, 6:59 PM ET

On February 24, Leigh Morgan, a member of the Board of Directors (the “Board”) of the Company, the Compensation and Talent Committee of the Board, and a member and chair of the Nominating and Corporate Governance Committee of the Board, informed the Company that she does not intend to stand for reelection at the Company’s 2025 annual meeting of shareholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Leigh Morgan departed as Director at Kymera Therapeutics, Inc..

Action: does not intend to stand for reelection
Role: Director

Exact text from the filing

On February 24, Leigh Morgan, a member of the Board of Directors (the “Board”) of the Company, the Compensation and Talent Committee of the Board, and a member and chair of the Nominating and Corporate Governance Committee of the Board, informed the Company that she does not intend to stand for reelection at the Company’s 2025 annual meeting of shareholders.

View on SEC.gov

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-037588

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.